AIxCrypto Holdings, Inc.
Support and Resistance Levels
Past performance
News About AIXC
All events for AIXC
All deals for AIXC
Financial Ratios
Financial Statements
AIXC vs Sector & Peers
About AIxCrypto Holdings, Inc.
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025. Website aixcrypto.ai
Headquarters El Segundo, CA, US